The hearing deadline is October 13, 2026 — a timely request stays the suspension. The outcome is binary: if the Panel denies the appeal, the stock faces immediate delisting and likely a significant price drop. Monitor the hearing date and any compliance plan details. The company's ability to regain compliance is uncertain.
Price Chart
Executive Summary
POMDOCTOR received a Nasdaq staff delisting determination on October 6, 2026, because its ADS bid price closed below $1.00 for 30 consecutive business days (Aug 24 – Oct 5, 2026). Because the company effected a 1-for-18 reverse stock split on June 22, 2026 (within the prior year), it is ineligible for the standard 180-day compliance period. The company intends to appeal by October 13, 2026, which will stay the suspension pending a hearing, but there is no assurance of success.
Key Facts
- Nasdaq staff determination letter received October 6, 2026, citing bid price below $1.00 for 30 consecutive business days (Aug 24 – Oct 5, 2026).
- Company ineligible for 180-day compliance period due to 1-for-18 reverse stock split on June 22, 2026, within the prior one-year period (Nasdaq Rule 5810(c)(3)(A)(iv)).
- Unless a hearing is timely requested by October 13, 2026, trading will be suspended at the open on October 15, 2026, and Nasdaq will file a Form 25-NSE to delist.
- Company intends to request a hearing to appeal and present a compliance plan; a timely request stays the suspension pending the Panel's decision.
- No assurance that the Panel will grant an extension, that the company will regain compliance, or that the appeal will be successful.
Financial Impact
Delisting determination directly threatens the continued listing of the company's securities on The Nasdaq Global Market — the sole exchange for its ADSs. Failure to regain compliance could result in delisting, which would severely impact liquidity and marketability of the ADSs.
Risk Factors
- Nasdaq delisting if the Panel denies the appeal or the company fails to regain compliance.
- Potential loss of liquidity and marketability of the ADSs if delisted.
- No assurance that the company will regain or maintain compliance with the Minimum Bid Price Requirement or any other Nasdaq continued listing requirement.
- The company's ability to regain compliance is uncertain.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-108499 |
| Document: ea030814601ex99-1.htm | 0001213900-26-108499 |
| Document: 0001213900-26-108499-index-headers.html | 0001213900-26-108499 |
| Document: 0001213900-26-108499-index.html | 0001213900-26-108499 |
| Document: 0001213900-26-108499.txt | 0001213900-26-108499 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 6-K | $0.5314 $1.13 | ▲ +112.65% | ▲ +112.79% | $1.13 (+112.65%) |
Oct 9, 2026 17d ago | 6-K | $0.6210 $0.5310 | ▲ +14.49% | ▲ +13.00% | $1.13 (−81.96%) |
Sep 30, 2026 26d ago | 6-K | $0.9350 $0.8490 | ▼ −9.20% | ▼ −11.11% | $1.13 (+20.86%) |
Sep 24, 2026 4w ago | 6-K | $0.9700 $0.9200 | ▼ −5.15% | ▼ −4.74% | $1.13 (+16.49%) |
Sep 10, 2026 6w ago | 6-K | $0.7423 $0.8290 | ▲ +11.68% | ▲ +12.18% | $1.13 (+52.23%) |
Aug 27, 2026 8w ago | 6-K | $0.9501 $0.8696 | ▼ −8.47% | ▼ −8.74% | $1.13 (+18.93%) |
Aug 10, 2026 11w ago | 6-K | $1.09 $0.8755 | ▼ −19.68% | ▼ −19.63% | $1.13 (+3.67%) |
Aug 3, 2026 12w ago | 6-K | $0.6880 $1.09 | ▲ +58.43% | ▲ +56.40% | $1.13 (+64.24%) |
Jul 15, 2026 14w ago | 6-K | $1.51 $0.8011 | ▼ −46.95% | ▼ −45.97% | $1.13 (−25.17%) |
Jul 13, 2026 15w ago | 6-K | $1.42 $1.13 | ▼ −20.42% | ▼ −19.64% | $1.13 (−20.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers